The drug, from biotech company Sarepta Therapeutics, will need to prove in an ongoing clinical trial that it improves physical function and mobility in patients with Duchenne muscular dystrophy in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback